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Cancer is known as the tsunami because it is the third leading 
cause of deaths in Iran. Almost all cancer cases have been 
diagnosed at the last stages and usually a patient loss the golden 
time due to the compatibility issues with chemo-therapy. 
Targeted therapy could be a gold standard therapeutic way to 
treat cancer at its best time. 
Letter to Editor 
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SUMMARY 
Cancer is known as the most common cause of 
death in the world and metastasis is the essential step 
in this disease which is relate to patients death (1).   
The CXCR4/CXCL12 pathway plays a pivotal role 
in the metastasis and malignancy of cancer 
reasoning high invasive properties of cancer cells. 
CXCR4 is expressed in many cancer cells is 
responsible for to the migration of cancerous cells to 
the specific tissues secreting CXCL12 (e.g., liver, 
lymph nodes, bones and lung) (2, 3). At least 20 
types of cancers can express CXCR4 which is  a 
crucial factor in the development and metastasis of 
about 75% of all cancers including gastrointestinal, 
skin, head and neck, breast, ovarian, prostate, renal, 
Bonding of CXCL12 to CXCR4 in the surface of 
cancer cells triggers a series of essential processes 
such as movement of malignant cells, 
chemoattraction, angiogenesis and cell adhesion 
which are important for cancer progression (5). 
There is a great enthusiasm for the operation of 
CXCR4/CXCL12 as a target for cancer therapy. The 
role of CXCR4/CXCL12 axis in cancers is as 
follows: 1) affecting CXCR4 expression in primary 
tumor cells. 2) Reinforcing other cancer therapy. 3) 
Modulation the immune response (6).  
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Xia et al. demonstrated that effecter B cells killed 
tumor cells by CXCR4/CXCL12 pathway (7).  
 Moreover, it has been demonstrated that CXCR4 
antagonists reduce intraperitoneal spread of tumor 
cells and increase necrosis and apoptosis of tumor 
cells. The CXCR4 antagonist, AMD3100 and 
Plerixa for are the most common among the agents 
which inhibiting CXCL12/CXCR4 axis and have a 
role in the inhibition of metastasis via targeting 
CXCR4-CXCL12 axis (6). Plerixa for is a FDA 
approved antagonist for non-Hodgkin lymphoma 
(NHL) and multiple myeloma (8). 
Some studies have indicated the reduction of cancer 
cells migration by natural substances and drugs   
which attenuate the CXCR4 expression and it can be 
a promise strategy to decrease metastatic inhibition 
(9). 
Dear editor, Cancer therapy has attracted the 
attention of many researchers around the world and a 
lot of works has been done in this regard. So far 
different therapeutic strategies such as treatment 
with CXCR4 inhibitory antagonists and drugs have 
been used to decrease the migration and metastasis 
of cancer cells toward specific tissues. Nevertheless, 
there are scarce clinical trials for treatment of 
patients with targeting CXCR4. 
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